Abstract
Metaiodobenzylguanidine (MIBG) labelled with iodine-131 (131I) has become a well established therapeutic tool for inoperable metastastic tumours of paraganglioma. There are different pharmacological substances known to interfere with MIBG-uptake which may result in a false negative MIBG scan. We present the case of a 26-year-old male polytoxicomanic patient with metastatic paraganglioma, who underwent MIBG therapy. During earlier therapies, MIBG uptake in the metastatic lesions was very high. A post-therapeutic whole-body scan subsequent to recent 131I-MIBG therapy failed to detect the vast majority of metastatic lesions-except for two. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) showed metastases with a similar distribution to the initial MIBG scan. The possible reasons for the discrepancy in the findings of the MIBG scans and the 18F-FDG-PET scan are discussed with special emphasis on drug intake prior to MIBG administration, increased MIBG turn-over and unknown drug mixture interference with MIBG uptake.
References
1 Proff P, Babin-Ebell J, Müller JG, Hopp H, Elert O. Paragangliom der Aorta ascendens. Zeitschrift für Herz-, Thorax-und Gefäßchirurgie 2000;14:258–63.
2 Razakaboay M, Maillefert JF, Wendling D, Juvin R, Toussirot E, Tavernier C, et al. Bone metastases from a paraganglioma. A review of five cases. Rev Rhum Engl Ed 1999;66:86–91.
3 Hiller WF, Scheumann GF, Dralle H. Diagnosis and surgical treatment of extra-adrenal pheochromocytoma. Chirurg 1993;64:36–42.
4 Bomanji J, Britton KE, Ur E, Hawkins L, Grossmann A, Besser GM. Treatment of malignant pheochromozytoma, paraganglioma and carcinoid tumors with 131I-metaiodbenzylguainidine. Nucl Med Commun 1993;14:856–61.
5 Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localisation of pheochromocytoma. N Engl J Med 1981;305:12–7.
6 Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648–58.
7 Bomanji JB, Hyder SW, Gaze MN, Gacinovic S, Costa DC, Coulter C, et al. Functional imaging as an aid to decision-making in metastatic paraganglioma. Br J Radiol 2001;74:266–9.
8 Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35:269–76.
9 Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled metaiodobenzylguanidine (MIBG). Nucl Med Commun 1992;13:513–21.
10 Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodbenzylguanidine: a review of its biodisribution and pharmacokinetics, drug interactions, cytotoxity and dosimetry. Eur J Nucl Med 1994;21:545–59.
11 Schwarz KB, Driver I, Lewis IJ, Taylor RE. Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis. Br J Radiol 1997;70:90–2. Comment on: Britton KE, Br J Radiol 1997;70:969.
